Skip to main content

EMBL Raises 10M Euros for New Technology Fund

NEW YORK, Dec. 10 – The European Molecular Biology Laboratory has raised 10 million euros ($8.9 million) for its first technology fund, which will look to invest in start up companies emerging from the research center. 

The European Molecular Biology Laboratory Enterprise Management fund, or EMBLEM, received funds from investors including  3i of the UK, BankInvest of Denmark, and Marco Polo of Spain. 

EMBL hopes to raise an additional seven million euros and to close the fund next year. 

EMBL, which has spun off such companies as Lion Bioscience, Cenix BioScience, Cellzome, and Gene Bridges, hopes that the new fund will help it to commercialize more emerging technologies. 

“With the EMBL Technology Fund we have created another vital building block necessary for the successful overall implementation of technology transfer at EMBL,” Gabor Lamm, managing director of EMBLEM, said in a statement released last week.

EMBL of Heidelberg, Germany, is a basic research institute. It receives its funding from 16 member states, including most of the EU, Switzerland, and Israel.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.